Clinical Trial Update: A Study to Examine Anktiva for the Treatment of COVID-19. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update indicating Anktiva (N-803) is being studied for treating Post-acute sequelae of SARS-CoV-2 infection (Long COVID), with recruitm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Anktiva (N-803)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Long COVID, Long COVID Syndrome | Phase 2 | Status: RECRUITING